Abiopharma

Update to the Dividend Distribution Policy

Dividend Distribution Q4, 2025 - NIS 360,000,000

Max (in parenthesis) published the results of a public tender for the issuance of commercial papers 6

Conference call to review the financial statements for 2025 on 30.3.26 at 15:00

The District Court rejected a motion for a class action against subsidiaries regarding the sale of Alrov

Conference call to review the financial statements for 2025 on March 31, 2026 at 14:00

Dormant shares

Events and transactions

Novartis IgAN data in New England Journal of Medicine showFabhalta® slowed kidney function decline by 49.3%

Change in holdings of interested parties/officers